Journal of Reproduction & Infertility

Journal of Reproduction & Infertility

Clinical Efficacy of Follitropin Alfa in GnRH-Antagonist Protocols: A Prospective Observational Phase IV Study on the Use of Biosimilar Follitropin Alfa r-hFSH in Assisted Reproductive Technology in a Routine Care Setting

Authors
Georg Griesinger 1
Thilo Schill 2
Michael Sator 3
Michael Schenk 4
Jan-Steffen Krüssel 5
1 Sektion Für Gynaekologische Endokrinologie und Reproduktionsmedizin, Klinik Für Frauenheilkunde & Geburtshilfe (Gynaekologie), Universitaetsklinikum Schleswig-Holstein-Campus Luebeck, Luebeck, Germany
2 MVZ Kinderwunschzentrum Langenhagen-Wolfsburg, Langenhagen, Germany
3 Kinderwunsch im Zentrum GmbH, Tulln an der Donau, Australia
4 Das Kinderwunsch Institut Schenk GmbH, Dobl b. Graz, Australia
5 Universitaeres interdisziplinäres Kinderwunschzentrum Duesseldorf (UniKiD), Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Duesseldorf, Duesseldorf, Germany
10.18502/jri.v22i2.5798
Abstract
Background: This phase IV routine care study evaluated ovarian responses when using a biosimilar follitropin alfa r-hFSH (Bemfola ® ) for controlled ovarian stimulation (COS) in women undergoing assisted reproductive technology (ART) treatment who were pituitary-suppressed with a gonadotrophin-releasing hormone (GnRH) antagonist. Methods: This multicenter, prospective, non-comparative, non-interventional study (Germany/Austria) was conducted with 885 women (Mean age of 34.0±4.4 years) for whom COS with Bemfola ® and GnRH-antagonist for pituitary suppression were applied as part of in vitro fertilization (IVF) treatment with/without intracytoplasmic sperm injection (ICSI) observing routine clinical-practice protocols. Primary endpoint was the number of retrieved cumulus-oocyte-complexes (COCs). Results: Among 986 ART cycles, COS was given for 9.9±1.8 days (First-day r-hFSH dose of 220.7±68.9 IU; mean total dose of 2184.3±837.5 IU). It was revealed that 99.1% of cycles resulted in follicular puncture, with mean of 10.7±6.6 oocytes retrieved. Successful fertilization took place after IVF/ICSI in 93.8% of follicular punctures. Freeze-all was performed in 14.2% of cycles. Fresh embryo transfer was performed in 76.9% of cycles with follicular puncture; mean day of transfer was 3.5±1.3 and average number of transferred embryos was 1.76±0.50. Clinical pregnancy rate was 30.2% of embryo-transfer cycles and 23.4% of started cycles. Sixty-nine reports of ovarian hyperstimulation syndrome (7.0% of started cycles) were documented. Conclusion: COS with Bemfola ® in GnRH-antagonist IVF/ICSI protocols in a routine care setting led to an appropriate ovarian response allowing oocyte retrieval in 99.1% of initiated cases.
Keywords
Assisted Reproductive Technology
Biosimilar pharmaceuticals
Follitropin alfa
gonadotropin
releasing hormone antagonist
  1. Wolzt M, Gouya G, Sator M, Hemetsberger T, Irps C, Rettenbacher M, et al. Comparison of pharmacokinetic and safety profiles between Bemfola(®) and Gonal-f(®) after subcutaneous application. Eur J Drug Metab Pharmacokinet. 2016;41(3):259-65.
  2. Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. Reprod Biomed Online. 2015;30(5):504-13.
  3. Niederberger C, Pellicer A, Cohen J, Gardner DK, Palermo GD, O’Neill CL, et al. Forty years of IVF. Fertil Steril. 2018;110(2):185-324.e5.
  4. Imthurn B, McVeigh E, Stiller R, Arnold M, Pringle F, Irps C, et al. Evaluation of the use and handling of three different pen systems considered for in vitro fertilization treatment. Expert Opin Drug Deliv. 2014;11(12):1859-64.
  5. Quintero LA, Verdú Merino V, Olivares Vela R, Rayward J, Torres Afonso A, Báez Quintana D, et al. An evaluation by potential IVF/donor oocyte patients of the use and handling of the Bemfola® Pen compared with the Gonal-f® Pen and Puregon Pen®. Revista Iberoamericana de Fertilidad y Reproducción Humana. 2017; 34:64-73.
  6. Saunders H, de la Fuente Bitaine L, Eftekhar C, Howles CM, Glaser J, Hoja T, et al. Functionality of a novel follitropin alfa pen injector: results from human factor interactions by patients and nurses. Expert Opin Drug Deliv. 2018;15(6):549-58.
  7. Blumenauer V, Czeromin U, Fehr D, Fiedler K, Gnoth C, Krüssel JS, et al. D.I.R annual 2017 - the German IVF-registry. J Reproduktionsmed Endokrinol. 2018;15:217-50.
  8. Van Tilborg TC, Oudshoorn SC, Eijkemans MJ, Mochtar MH, Van Golde RJ, Hoek A, et al. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis. Hum Reprod. 2017;32(12):2485-95.
  9. Nastri CO, Teixeira DM, Moroni RM, Leitão VM, Martins WP. Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention. Ultrasound Obstet Gynecol. 2015;45(4):377-93.
  10. Roque M, Valle M, Kostolias A, Sampaio M, Geber S. Freeze-all cycle in reproductive medicine: current perspectives. JBRA Assist Reprod. 2017;21(1):49-53.
  11. Griesinger G, Von Otte S, Schroer A, Ludwig AK, Diedrich K, Al-Hasani S, et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study. Hum Reprod. 2007;22(5):1348-52.
Journal of Reproduction & Infertility
Volume 22, Issue 2
Spring 2021
Pages 116-124